The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Keflex 125 mg/5 ml Powder for Oral Suspension

Flynn Pharma LimitedPA1226/002/002

Main Information

Trade NameKeflex 125 mg/5 ml Powder for Oral Suspension
Active SubstancesCephalexin monohydrate
Dosage FormPowder for oral suspension
Licence HolderFlynn Pharma Limited
Licence NumberPA1226/002/002

Group Information

ATC CodeJ01DB First-generation cephalosporins
J01DB01 cefalexin


License statusAuthorised
Licence Issued14/04/1977
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back